With both the discount rate and future P/E metrics remaining essentially stable, there has been no material change to Adient's consensus analyst price target, which holds steady at $24.55.
What's in the News
- Adient launched an industry-first mechanical massage seat solution, debuting in GAC-Trumpchi's new M8 PHEV, with mass production underway and global customer interest.
- The company maintained its fiscal 2025 earnings guidance, expecting positive momentum to continue, barring potential tariff impacts.
- Adient recorded a $333 million noncash goodwill impairment for the second quarter of 2025.
- No shares were repurchased in Q2 2025; the company has completed buyback of 12.4 million shares (13.7%) for $365.07 million since November 2022.
Valuation Changes
Summary of Valuation Changes for Adient
- The Consensus Analyst Price Target remained effectively unchanged, at $24.55.
- The Discount Rate for Adient remained effectively unchanged, moving only marginally from 11.94% to 12.06%.
- The Future P/E for Adient remained effectively unchanged, moving only marginally from 8.69x to 8.72x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.